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Abstract
Pseudomonas aeruginosa, the principal respiratory pathogen in cystic ﬁbrosis (CF) patients, is ubiquitous in the environment. Initial
P. aeruginosa isolates in CF patients are generally environmental in nature. However, little information regarding seasonality of P. aeruginosa
acquisition is available. We conducted a retrospective study to evaluate the seasonality of initial P. aeruginosa acquisition in young children
with CF in the USA using the Cystic Fibrosis Foundation National Patient Registry from 2003 to 2009. Additionally, we assessed whether
seasonal acquisition varied by climate zone. A total of 4123 children met inclusion criteria and 45% (n = 1866) acquired P. aeruginosa during
a mean 2.0 years (SD 0.2 years) of follow up. Compared with winter, increased P. aeruginosa acquisition was observed in summer (incidence
rate ratio (IRR): 1.22; 95% CI: 1.07–1.40) and autumn (IRR: 1.34; 95% CI: 1.18–1.52), with lower acquisition observed in spring (IRR: 0.81;
95% CI: 0.70–0.94). Seasonal variations in P. aeruginosa acquisition rates in the temperate and continental climate zones were similar to
those in the overall cohort. In contrast, no signiﬁcant seasonal effect was observed in the dry climate zone. In a corresponding analysis, no
seasonal difference was observed in the rate of acquisition of Staphylococcus aureus, another common CF respiratory pathogen. These
results provide preliminary support that climatic factors may be associated with initial P. aeruginosa acquisition in CF patients. Investigation
and identiﬁcation of speciﬁc risk factors, as well as awareness of seasonal variation, could potentially inform clinical recommendations
including increased awareness of infection control and prevention strategies.
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Introduction
Infectious diseases often exhibit temporal and seasonal variation
in incidence. These patterns depend upon the speciﬁc pathogen
and host, the mode of transmission and the environmental
characteristics [1,2]. Pseudomonas aeruginosa is a ubiquitous
environmental organism and the most signiﬁcant pathogen in
cystic ﬁbrosis (CF) lung disease. The prevalence of P. aeruginosa
infection among CF patients increases with age, with positive
respiratory tract cultures reported for c.20–30% of infants, 30–
40% of children aged 2–10 years, 60% of adolescents and 80% of
adults in the USA [3]. Earlier initial P. aeruginosa acquisition has
been associated with increased morbidity and mortality [4–6].
Patients with CF are initially infected with environmental
isolates of P. aeruginosa [7,8]. Regardless of treatment, patients
commonly have a period of intermittent isolation of P. aerugin-
osa from the respiratory tract before becoming chronically
infected [9–11]. Eventually there appears to be clonal selection
of a speciﬁc P. aeruginosa genotype that then undergoes genetic
adaptation within the CF airway [8,12].
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Although the seasonal acquisition of P. aeruginosa in CF
patients has been investigated [13,14], these studies have been
limited to small sample sizes in geographically homogeneous
areas. Insight into seasonal variations in the rate of P. aerugin-
osa acquisition throughout the USA could elucidate climatic
factors driving host–pathogen interactions and inform recom-
mendations for monitoring respiratory cultures in young
children with CF. The objectives of this study were therefore
to: (i) evaluate the seasonal acquisition of P. aeruginosa in
young children with CF in the USA and (ii) determine whether
seasonal acquisition varied by climate zone.
Methods
We performed a retrospective study using the Cystic Fibrosis
Foundation (CFF) National Patient Registry data from
1 January 2003 to 31 December 2009. The Registry contains
detailed demographic and clinical information on CF patients
treated at all US CFF-accredited centres, who comprise >80%
of diagnosed US CF patients. Data are entered at each clinical
encounter, including results of respiratory cultures. Since
2003, CFF clinical care guidelines have included obtaining
quarterly cultures (i.e. four times per year) [15].
The study population included all patients in the Registry
born in 2003 or later who had at least one respiratory culture
recorded before 2 years of age and whose ﬁrst recorded
culture was negative for P. aeruginosa. Therefore, only children
up to 6 years of age were included in the study. The primary
outcome was initial P. aeruginosa acquisition (i.e. based on the
ﬁrst culture from which P. aeruginosa was isolated). The
primary exposure was season of P. aeruginosa acquisition,
deﬁned as spring (March–May), summer (June–August),
autumn (September–November) and winter (December–
February).
Seasonality within the US is geographically variable; there-
fore, we evaluated potential seasonal differences within climate
zones using the revised K€oppen–Geiger Climate classiﬁcation
[16]. Brieﬂy, in this classiﬁcation scheme a total of ﬁve broad
regions (Tropical, Dry, Temperate, Continental and Polar) are
deﬁned based on meteorological variables. We linked locations
from individual-level zip code data from the CFF Registry,
taken as the zip code in the year in which P. aeruginosa was
acquired or the year of the last clinical visit recorded in the
Registry (for those remaining P. aeruginosa free), to the
K€oppen–Geiger climate classiﬁcation using ARCGIS version
10.1 (ESRI, Redlands, CA, USA). In the US CF population, four
climate zones are represented (tropical, dry, temperate and
continental) (Fig. 1). Due to the minimal number of patients
residing in the tropical zone (n = 37), seasonal variability in this
zone was not evaluated; these patients were retained in the
overall seasonal analysis.
Descriptive statistics were produced. Student’s t-tests with
unequal variances were used to compare continuous variables
and chi-square tests compared categorical variables between
acquisition status.
Incidence of P. aeruginosa was calculated for each season
over the study period. The denominator for these rates was
the number of persons under observation and at risk for initial
P. aeruginosa acquisition during each season, and the numer-
ator consisted of the cases occurring during that season. Due
to the important role that culture frequency may play in
observed incidence, the average number of cultures per
person for each of the seasons was also evaluated.
To evaluate the association of season with P. aeruginosa
incidence, we used Poisson log-linear regression with
quasi-likelihood and included the number of individuals at risk
as the offset term. Winter season was the baseline for all
comparisons, as we hypothesized that P. aeruginosa incidence
would be lowest during this season. Results are presented as
incidence rate ratios (IRRs) and corresponding 95% CIs. These
analyses were then repeated for each climate zone separately.
We performed three sensitivity analyses. We evaluated
whether the seasonal associations observed in the entire
cohort were seen in individuals with different cystic ﬁbrosis
transmembrane conductance regulator mutation classes
FIG. 1. Climate zones of the continental USA based on the revised Koppen–Geiger climate classiﬁcation (adapted from Peel et al. [16]).
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(DF508 homozygous, heterozygous and other), and age at date
of culture (<2 or ≥2 years). We also limited the Poisson
analyses by deﬁning the persons at risk in each season as only
those who had a culture recorded in the Registry during that
season. Finally, hypothesizing that Staphylococcus aureus would
not exhibit a seasonal pattern of acquisition, we replicated the
above analyses with season of initial acquisition of S. aureus as
the primary outcome of interest, among patients in the
Registry born in 2003 or later who had at least one respiratory
culture recorded before 2 years of age and whose ﬁrst
recorded culture was negative for S. aureus.
The study was approved by the CFF Registry Committee
and the University of Washington Institutional Review Board.
All analyses were conducted using STATA 12.0 (StataCorp,
College Station, TX, USA).
Results
The study cohort consisted of 4123 patients. Of these, 45%
(n = 1866) acquired P. aeruginosa and 55% (n = 2257)
remained P. aeruginosa-negative during a mean of 2.0 years
(SD = 0.2 years) of observation (Fig. 2). A total of 32 698
cultures were performed during follow-up in these individuals.
The majority of cultures (90%) were oropharyngeal; however,
other culture types included sputum (expectorated or
induced) (8%) and bronchoscopic (1%). The demographic
and clinical characteristics of the cohort are presented in
Table 1. Children acquiring P. aeruginosa tended to be diag-
nosed later, were less likely to be diagnosed by newborn
screening and were more likely to be DF508 homozygous
compared with those that did not acquire P. aeruginosa.
The overall P. aeruginosa incidence rate during the study
period was 16.5/1000 person-months (95% CI: 15.7–17.2) and
the median age of P. aeruginosa acquisition was 19 months.
Figure 3 displays P. aeruginosa incidence for each season during
the study period. The highest rates of P. aeruginosa acquisition
were observed in the summer and autumn for each year, with
peak P. aeruginosa incidence occurring in autumn for all study
years except 2008. The overall incidence rates in winter,
spring, summer and autumn, respectively, were 15 (95% CI:
13–16), 12 (95% CI: 11–13), 18 (95% CI: 17–20) and 20/1000
person-months (95% CI: 18–22). Figure 3 also displays the
average number of cultures in each season. It can be seen that
the number of cultures per person per season steadily
increased over the study period. At the beginning of the study
period in 2003, the average number of cultures per patient per
season was 0.4, rising to approximately 1 in 2009, probably
reﬂecting improved adherence to CFF guidelines regarding
quarterly cultures. The average culture rate from 2003 to 2009
was similar for all seasons (0.9 cultures/person-season).
The results of Poisson regression models evaluating the
association between P. aeruginosa incidence and season of
acquisition are presented in Table 2. Compared with winter,
signiﬁcantly higher P. aeruginosa incidence was observed in
summer (IRR: 1.22; 95% CI: 1.08–1.39) and autumn (IRR: 1.34;
95% CI: 1.18–1.52), whereas signiﬁcantly lower P. aeruginosa
incidence was observed in spring (IRR: 0.81; 95% CI: 0.70–0.93).
The distribution of patients by climate zone was as follows:
289 (7%) in dry, 1679 (43%) in temperate and 1913 (49%) in
continental climate zones. The overall P. aeruginosa incidence
in these regions was 14 (95% CI: 12–17), 17 (95% CI: 16–18)
and 17/1000 (95% CI: 16–18) person-months for dry,
temperate and continental climate zones, respectively. A
minimal number of patients that changed zip code also changed
climate zone (n = 54) while under observation. The seasonal
variation in P. aeruginosa acquisition in the temperate and
continental climate zones were similar to the overall cohort
(Table 2). In contrast, a signiﬁcant seasonal effect was not
observed in the dry climate zone.
In sensitivity analyses, the seasonal pattern of P. aeruginosa
acquisition seen in the entire cohort was also seen in each
FIG. 2. Flow chart of study cohort for evaluation of acquisition of
Pseudomonas aeruginosa (Pa). [This ﬁgure was corrected on 04/07/2013,
after original online publication 25/06/2013. In the bottom right hand
box “Acquired Pa during follow-up”, “n = 2265” has been corrected
to “n = 1866”.]
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cystic ﬁbrosis transmembrane conductance regulator mutation
subgroup (DF508 homozygous, heterozygous or other),
among those with age at date of culture <2 or ≥2 years, and
when the persons at risk in each season were deﬁned as only
those who had a culture recorded in the Registry during that
season (data not presented).
Finally, we repeated the season of acquisition analyses for
S. aureus. This study population differed slightly from that for
the P. aeruginosa analysis because of the larger number of
individuals excluded due to ﬁrst recorded culture positive for
S. aureus (n = 1326). Hence, the study cohort consisted of
3196 patients. The demographic and clinical characteristics of
this cohort were similar to those of the P. aeruginosa
acquisition cohort (Table 1). A total of 1987 (62%) individuals
acquired S. aureus during the study and 1209 (38%) remained
S. aureus-negative. The overall S. aureus incidence was 26.7/
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FIG. 3. Seasonal incidence rates for
Pseudomonas aeruginosa acquisition among
young children with cystic ﬁbrosis in the
USA from 2003 to 2009. Whiskers repre-
sent 95% conﬁdence intervals.
Pseudomonas aeruginosa
(n = 4123)
Staphylococcus aureus
(n = 3196)
P. aeruginosa
acquired
(n = 1866)
P. aeruginosa
negative
(n = 2257)
S. aureus
acquired
(n = 1987)
S. aureus
negative
(n = 1209)
Male (%) 52a 47 52a 48
Race/ethnicity (%)
Non-Hispanic White 84a 84 84a 82
Black 6 5 5 7
Other 10 11 2 2
Mean age (SD) at diagnosis, months 2.2 (4.0) 2.3 (4.2) 2.5 (4.3) 2.3 (4.4)
Identiﬁed by newborn screening (%) 35a 50 34a 53
Cystic ﬁbrosis transmembrane conductance regulator mutation
DF508 homozygous 53a 41 50a 46
DF508 heterozygous 36 44 37 42
Other 11 15 13 12
SD, standard deviation.
ap <0.05.
TABLE 1. Characteristics of the
study cohorts, by Pseudomonas aeru-
ginosa and Staphylococcus aureus
acquisition status
TABLE 2. Seasonal incidence of Pseudomonas aeruginosa and Staphylococcus aureus acquisition among children <6 years of age
with cystic ﬁbrosis in the USA from 2003 to 2009
Overall
IRR (95% CI)
Climate zone
Dry
IRR (95% CI)
Temperate
IRR (95% CI)
Continental
IRR (95% CI)
Pseudomonas aeruginosa
Winter Ref. Ref. Ref. Ref.
Spring 0.81 (0.70–0.93) 0.69 (0.40–1.19) 0.83 (0.67–1.04) 0.80 (0.64–1.00)
Summer 1.22 (1.08–1.39) 0.91 (0.55–1.50) 1.14 (0.94–1.39) 1.36 (1.12–1.64)
Autumn 1.34 (1.18–1.52) 1.11 (0.69–1.78) 1.21 (1.01–1.47) 1.55 (1.28–1.88)
Staphylococcus aureus
Winter Ref. Ref. Ref. Ref.
Spring 0.99 (0.87–1.12) 0.96 (0.61–1.51) 0.99 (0.81–1.20) 0.99 (0.82–1.19)
Summer 0.98 (0.87–1.11) 0.82 (0.51–1.31) 0.96 (0.79–1.17) 1.06 (0.89–1.27)
Autumn 1.11 (0.99–1.25) 1.13 (0.74–1.74) 1.04 (0.86–1.25) 1.15 (0.97–1.38)
IRR, incidence rate ratio.
From Poisson regression models with the number of individuals at risk as the offset term. Winter season is the reference season. Results in bold are statistically signiﬁcant
(p <0.05).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E483–E489
E486 Clinical Microbiology and Infection, Volume 19 Number 11, November 2013 CMI
1000 person-months (95% CI: 25.6–27.9) and the median age
of S. aureus acquisition was 18 months. In contrast to the
observed ﬁndings with P. aeruginosa, there was little variation
in S. aureus incidence by season (26/1000 person-months in
spring (95% CI: 24–28); 26/1000 person-months in summer
(95% CI: 24–28); 29/1000 person-months in autumn (95% CI:
26–31); and 26/1000 person-months in winter (95% CI: 24–
29)) (Fig. 4). Poisson regression models showed no difference
in S. aureus incidence by season for the cohort as a whole or in
each climate zone (Table 2).
Discussion
We observed signiﬁcant seasonal variation in the rate of initial
P. aeruginosa acquisition in a large US cohort of young children
with CF over a 7-year period. Compared with winter,
incidence of initial P. aeruginosa acquisition was signiﬁcantly
higher in summer and autumn and lower in spring. These
seasonal differences in P. aeruginosa acquisition rates were
seen in the continental and temperate climate zones but not in
the dry zone, though our power to detect seasonal variation in
the dry zone was limited by the small number of individuals
residing in this zone. We also evaluated seasonal patterns in
S. aureus acquisition as a comparison with an outcome that we
hypothesized would not have a seasonal difference and found
no seasonal variation in S. aureus incidence rates in the overall
cohort or in any climate zone. These results strongly suggest
that climatic factors that vary with season inﬂuence initial
P. aeruginosa acquisition in CF patients.
To date, only two single centre studies have reported
seasonal patterns of P. aeruginosa acquisition in children with
CF, and to our knowledge no study has evaluated seasonal
patterns of S. aureus acquisition in children with CF. In a
retrospective medical record review of 300 Danish CF patients
from 1965 to 1990, Johansen and Høiby [14] also reported
seasonal variation in acquisition, with higher acquisition of
P. aeruginosa from October to March compared with April–
September. Although no quantitative results were presented,
Farrell et al. [13] reported no differences in P. aeruginosa
acquisition by season in 120 patients diagnosed through
newborn screening in Wisconsin from 1985 to 1991, though
their results may have been limited by small sample size.
Limited information is available regarding the seasonality of
P. aeruginosa infection in other settings. Perencevich et al. [17]
investigated the seasonality of bacterial infections (including
hospital-acquired) among patients hospitalized at a single
tertiary-care centre from 1998 to 2005 and found increased
cases of P. aeruginosa and other gram-negative bacteria in
summer months compared with winter. Further, they found
that for a 10% increase in temperature there was a 17%
increase (95% CI: 4–31%) in P. aeruginosa infections in warmer
months (May–September) but not cooler months (October–
April). Other studies investigated the temporality of P. aeru-
ginosa infections in otitis externa [18–20] and keratitis [21] and
found increased rates of infection in summer and autumn
seasons.
Our ﬁnding of seasonal variation in P. aeruginosa acquisition
rates suggests that meteorological conditions such as temper-
ature, humidity or ambient air quality may be underlying risk
factors for age at initial P. aeruginosa infection [1]. Such
conditions could affect the density of P. aeruginosa in the
environment of children with CF or could play an indirect role
by inﬂuencing the activities of children during each season.
Several investigators have found an association between
P. aeruginosa prevalence and climatic factors, including warmer
temperatures and higher humidity. Recently, Collaco et al. [22]
investigated the role of environmental factors on CF lung
disease in three distinct cohorts. Though they did not focus
speciﬁcally on initial acquisition of P. aeruginosa, they showed
that higher ambient temperature was associated with greater
P. aeruginosa prevalence in both the USA and Australia.
High-humidity environments have been linked to P. aeruginosa
infections in non-CF infants [23], and rates of P. aerugin-
osa-related keratitis have been shown to vary by K€oppen
climate zone in Australia [24]. In addition, ambient air quality
could be a risk factor for initial P. aeruginosa acquisition, as
higher concentrations of particulate matter have been shown
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FIG. 4. Seasonal incidence rates for
Staphylococcus aureus acquisition among
young children with cystic ﬁbrosis in the
USA from 2003 to 2009. Whiskers repre-
sent 95% conﬁdence intervals.
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to adversely affect pulmonary exacerbation rates and lung
function among CF patients [25].
Respiratory viruses have been shown to be important
causative agents of pulmonary exacerbations in CF patients
[26], and virally mediated damage to the respiratory epithelium
could potentially predispose CF patients to bacterial airway
infection [27]. Interestingly, we did not observe higher rates of
P. aeruginosa acquisition in the winter, as might be expected if
viral infections were the major risk factor for P. aeruginosa
infection.
Risk factors in the environments of CF patients for initial
P. aeruginosa infection remain poorly understood. With the
recognition that initial P. aeruginosa acquisition is environmen-
tal in nature, recent investigations have focused on home [28]
and macro-environmental factors [22] associated with P. aeru-
ginosa infection in CF patients. In one small study, acquisition
from the home environment was shown to account for at
most 20% of all cases [29]. Other modes of acquisition
including person-to-person transmission, nosocomial, and
nebulizer equipment-related acquisition are rare. In a large
prospective observational study, Rosenfeld, et al. [28] were
unable to identify risk factors in the child’s environment (e.g.
hot tub exposure, day care, breastfeeding) associated with age
at initial P. aeruginosa acquisition.
There are several limitations to the present investigation.
First, the exact date of P. aeruginosa acquisition was unknown
for individuals; rather, the date of acquisition was considered
to be the date of positive culture. Second, in this observa-
tional study in young, generally pre-expectorating, children,
c.90% of cultures were of upper respiratory tract samples
(oropharyngeal swabs) rather than lower respiratory tract
samples (sputum or bronchoalveolar lavage ﬂuid). Oropha-
ryngeal cultures are known to have moderate speciﬁcity and
low sensitivity for lower airway P. aeruginosa [30]. Hence, it is
possible that seasonal patterns of lower airway P. aeruginosa
incidence differ from those observed in this study, though the
portal of entry for lower airway infection is likely to be the
upper airway. Third, we limited our analysis to initial
P. aeruginosa acquisition; we did not evaluate the seasonal
rates of chronic infection as we expected that the risk factors
would differ. Finally, we limited our cohort to children
diagnosed with CF before the age of 2 years and with a
maximum age of 6 years (since the Registry only began
collecting quarterly culture data in 2003 and data were only
available through 2009); this could affect the generalizability
of our results.
In summary, increased rates of initial P. aeruginosa acqui-
sition were observed in young CF patients in summer and
autumn compared with winter in this national study. Results
of such analyses could inform recommendations regarding
prevention strategies and clinical care, including reinforcing
the importance of regular follow-up visits with cultures,
particularly during higher-risk months and identifying high--
risk populations that might beneﬁt from more frequent
monitoring. Similar approaches could identify environmental
risk factors for other CF pathogens such as Burkholderia
cepacia.
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